A Clinical Trial to Evaluate the Effects of Two Supplements on Cognitive Function, Cognitive Performance, and Mood
11. august 2026 oppdatert av: BrainJuice
This study evaluates the effects of two liquid dietary supplements, BrainJuice Peach Mango (test product one) and BrainJuice ACTIVE Pomegranate Acai (test product two), on cognitive function, cognitive performance, and mood in healthy adults aged 18-57 who report concerns in these areas. The trial is a six-week, single-arm, open-label, virtual study enrolling 30 participants.
Participants will consume test product one (2.5 oz once daily) during Weeks 1 and 2, undergo a washout period during Weeks 3 and 4, and then consume test product two (2.5 oz once daily) during Weeks 5 and 6. Cognitive function will be assessed via standardized computerized cognitive assessments at Baseline, Week 2, Week 4, and Week 6, while perceptions of cognitive function, cognitive performance, and mood will be captured through self-reported questionnaires at Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
30
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Nevada
-
Las Vegas, Nevada, Forente stater, 89101
- Citruslabs
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
Tar imot friske frivillige
Ja
Beskrivelse
Inclusion Criteria:
- Be male or female
- Be aged 18-57
- Anyone experiencing concerns regarding all of the following over the past four weeks: Cognitive Function, Cognitive Performance, and Mood
- Anyone who is generally healthy - does not live with any uncontrolled chronic disease
- If taking oral over-the-counter supplements or herbal remedies targeted at cognitive function, cognitive performance, or mood, has been consistently taking these for at least 3 months prior to starting the study, and is willing to maintain this routine for the study duration
- Anyone who is a regular caffeine consumer without a history of caffeine sensitivity or intolerance
- Willing to maintain the same diet and exercise regimen consistently throughout the study duration
- Willing to limit caffeine consumption to one additional serving of caffeine outside of the test product i.e. one cup of brewed coffee (~100 mg), one matcha (~60 mg), two shots of espresso (~120 mg), or one cup of caffeinated tea (~50 mg)
- Resides in the United States
- Has access to a computer or tablet device
Exclusion Criteria:
- Anyone with pre-existing chronic conditions, including but not limited to oncological, uncontrolled hypertension (high blood pressure) or hypotension (low blood pressure), heart disease, diabetes and psychiatric disorders
- History of neurodegenerative disease (e.g., Alzheimer's, Parkinson's), history of traumatic brain injury (including concussions), stroke, epilepsy, or uncontrolled migraine
- History of mood disorders, such as depression, bipolar disorder, or seasonal affective disorder
- History of sleep disorders, such as insomnia, narcolepsy, or sleep apnea
- Anyone with a job that involves shift work that may be overnight or night hours
- Planning on introducing any products or any new forms of prescription medication or supplements that target cognitive function, cognitive performance, or mood, for the study duration
- Anyone with any allergies or sensitivities to any of the study product ingredients
- Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period)
- Anyone unwilling to follow the study protocol
- Anyone with a history of substance abuse
- Anyone who is currently a smoker or has been a smoker in the past 3 months
- Currently partaking in another research study or will be partaking in any other research study at any point during this study's duration
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: BrainJuice Supplement
|
All participants consume BrainJuice Peach Mango (test product one, 2.5 oz once daily) during Weeks 1 and 2, followed by a washout period during Weeks 3 and 4 with no test product, followed by BrainJuice ACTIVE Pomegranate Acai (test product two, 2.5 oz once daily) during Weeks 5 and 6.
There is no comparator or placebo arm.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Cognitive Assessment Score (Polygons)
Tidsramme: Baseline, Week 2, Week 4, and Week 6
|
Mean change in Polygons processing test score from Baseline, measured via computerized cognitive assessment
|
Baseline, Week 2, Week 4, and Week 6
|
|
Change in Cognitive Assessment Score (Double Trouble)
Tidsramme: Baseline, Week 2, Week 4, and Week 6
|
Mean change in Double Trouble selective attention and processing speed test score from Baseline, measured via computerized cognitive assessment
|
Baseline, Week 2, Week 4, and Week 6
|
|
Change in Cognitive Assessment Score (Feature Match)
Tidsramme: Baseline, Week 2, Week 4, and Week 6
|
Mean change in Feature Match focus and processing test score from Baseline, measured via computerized cognitive assessment
|
Baseline, Week 2, Week 4, and Week 6
|
|
Change in Cognitive Assessment Score (Paired Associates)
Tidsramme: Baseline, Week 2, Week 4, and Week 6
|
Mean change in Paired Associates memory task score from Baseline, measured via computerized cognitive assessment
|
Baseline, Week 2, Week 4, and Week 6
|
|
Change in Cognitive Assessment Score (Digit Span)
Tidsramme: Baseline, Week 2, Week 4, and Week 6
|
Mean change in Digit Span short-term memory and attention test score from Baseline, measured via computerized cognitive assessment
|
Baseline, Week 2, Week 4, and Week 6
|
|
Change in Cognitive Assessment Score (Spatial Planning)
Tidsramme: Baseline, Week 2, Week 4, and Week 6
|
Mean change in Spatial Planning executive function test score from Baseline, measured via computerized cognitive assessment
|
Baseline, Week 2, Week 4, and Week 6
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Self-Reported Focus
Tidsramme: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
Mean change in perceived focus from Baseline, assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
|
Change in Self-Reported Attention
Tidsramme: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
Mean change in perceived attention from Baseline, assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
|
Change in Self-Reported Concentration
Tidsramme: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
Mean change in perceived concentration from Baseline, assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
|
Change in Self-Reported Productivity
Tidsramme: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
Mean change in perceived productivity from Baseline, assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
|
Change in Self-Reported Alertness
Tidsramme: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
Mean change in perceived alertness from Baseline, assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
|
Change in Self-Reported Mental Clarity
Tidsramme: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
Mean change in perceived mental clarity from Baseline, assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
|
Change in Self-Reported Mood
Tidsramme: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
Mean change in perceived mood from Baseline, assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
|
Change in Self-Reported Mental Fatigue
Tidsramme: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
Mean change in perceived mental fatigue from Baseline, assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
|
Change in Self-Reported Motivation
Tidsramme: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
Mean change in perceived motivation from Baseline, assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
|
Change in Self-Reported Organization
Tidsramme: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
Mean change in perceived organization from Baseline, assessed via self-reported questionnaire
|
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
9. november 2025
Primær fullføring (Faktiske)
6. februar 2026
Studiet fullført (Faktiske)
6. februar 2026
Datoer for studieregistrering
Først innsendt
11. august 2026
Først innsendt som oppfylte QC-kriteriene
11. august 2026
Først lagt ut (Faktiske)
14. august 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
14. august 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
11. august 2026
Sist bekreftet
1. august 2026
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 20807 (Annen identifikator: Fred Hutch/University of Washington Cancer Consortium)
- legacy-20807
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .